KR20240006659A - 아자시티딘과 병용한 골수형성이상 증후군의 치료시 사용하기 위한 베네토클락스 투약 용법 - Google Patents
아자시티딘과 병용한 골수형성이상 증후군의 치료시 사용하기 위한 베네토클락스 투약 용법 Download PDFInfo
- Publication number
- KR20240006659A KR20240006659A KR1020237042682A KR20237042682A KR20240006659A KR 20240006659 A KR20240006659 A KR 20240006659A KR 1020237042682 A KR1020237042682 A KR 1020237042682A KR 20237042682 A KR20237042682 A KR 20237042682A KR 20240006659 A KR20240006659 A KR 20240006659A
- Authority
- KR
- South Korea
- Prior art keywords
- count
- nadir
- baseline
- absolute neutrophil
- blood cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163201749P | 2021-05-11 | 2021-05-11 | |
| US63/201,749 | 2021-05-11 | ||
| PCT/US2022/028429 WO2022240786A1 (en) | 2021-05-11 | 2022-05-10 | Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240006659A true KR20240006659A (ko) | 2024-01-15 |
Family
ID=84028499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237042682A Pending KR20240006659A (ko) | 2021-05-11 | 2022-05-10 | 아자시티딘과 병용한 골수형성이상 증후군의 치료시 사용하기 위한 베네토클락스 투약 용법 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220378811A1 (https=) |
| EP (1) | EP4337183A4 (https=) |
| JP (1) | JP2024517318A (https=) |
| KR (1) | KR20240006659A (https=) |
| CN (1) | CN117642161A (https=) |
| AU (1) | AU2022273023A1 (https=) |
| BR (1) | BR112023023677A2 (https=) |
| CA (1) | CA3219760A1 (https=) |
| IL (1) | IL308321A (https=) |
| MX (1) | MX2023013364A (https=) |
| WO (1) | WO2022240786A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10052346B2 (en) * | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
| KR20220004669A (ko) * | 2019-04-29 | 2022-01-11 | 이뮤노젠 아이엔씨 | 항-cd123 면역접합체를 포함하는 치료적 조합물 |
| JP2022537551A (ja) * | 2019-06-20 | 2022-08-26 | セルジーン・クオンティセル・リサーチ・インコーポレイテッド | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
| WO2021037933A1 (en) * | 2019-08-28 | 2021-03-04 | Astrazeneca Ab | Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer |
-
2022
- 2022-05-10 IL IL308321A patent/IL308321A/en unknown
- 2022-05-10 WO PCT/US2022/028429 patent/WO2022240786A1/en not_active Ceased
- 2022-05-10 US US17/741,359 patent/US20220378811A1/en not_active Abandoned
- 2022-05-10 JP JP2023569885A patent/JP2024517318A/ja active Pending
- 2022-05-10 AU AU2022273023A patent/AU2022273023A1/en not_active Abandoned
- 2022-05-10 CA CA3219760A patent/CA3219760A1/en active Pending
- 2022-05-10 EP EP22808145.1A patent/EP4337183A4/en not_active Withdrawn
- 2022-05-10 KR KR1020237042682A patent/KR20240006659A/ko active Pending
- 2022-05-10 BR BR112023023677A patent/BR112023023677A2/pt unknown
- 2022-05-10 MX MX2023013364A patent/MX2023013364A/es unknown
- 2022-05-10 CN CN202280048997.0A patent/CN117642161A/zh not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022273023A1 (en) | 2023-11-23 |
| MX2023013364A (es) | 2023-11-27 |
| US20220378811A1 (en) | 2022-12-01 |
| EP4337183A4 (en) | 2025-04-23 |
| WO2022240786A1 (en) | 2022-11-17 |
| EP4337183A1 (en) | 2024-03-20 |
| JP2024517318A (ja) | 2024-04-19 |
| IL308321A (en) | 2024-01-01 |
| CA3219760A1 (en) | 2022-11-17 |
| CN117642161A (zh) | 2024-03-01 |
| BR112023023677A2 (pt) | 2024-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gerhartz et al. | Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas [see comments] | |
| Marsh et al. | Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party | |
| Welschinger et al. | Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice | |
| JP2014040437A (ja) | （＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の組合せ使用 | |
| JP2019026647A (ja) | 骨髄抑制の処置 | |
| Gluzman-Poltorak et al. | Randomized comparison of single dose of recombinant human IL-12 versus placebo for restoration of hematopoiesis and improved survival in rhesus monkeys exposed to lethal radiation | |
| KR20240006660A (ko) | Cyp3a 억제제 및 아자시티딘과 병용한 골수형성이상 증후군의 치료시 사용하기 위한 베네토클락스 투약 용법 | |
| JP2023154026A (ja) | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 | |
| US20240190971A1 (en) | USE OF an anti-P-selectin antibody | |
| KR20240006659A (ko) | 아자시티딘과 병용한 골수형성이상 증후군의 치료시 사용하기 위한 베네토클락스 투약 용법 | |
| Robertson et al. | A dose-escalation study of recombinant human interleukin-18 in combination with ofatumumab after autologous peripheral blood stem cell transplantation for lymphoma | |
| HK40106739A (zh) | 与阿扎胞苷联合用於治疗骨髓增生异常综合征的维奈托克给药方案 | |
| WO2005007093A2 (en) | Uses of il-12 in hematopoiesis | |
| Leonard et al. | Novel agents for follicular lymphoma | |
| HK40106881A (zh) | 与cyp3a抑制剂和阿扎胞苷联合治疗骨髓增生异常综合征的维奈托克给药方案 | |
| Rattarittamrong et al. | CHOEP-21 chemotherapy for newly diagnosed nodal peripheral T-cell lymphomas (PTCLs) in Maharaj Nakorn Chiang Mai Hospital | |
| Al‐Omari et al. | Eltrombopag in Treating Post‐Allogeneic Hematopoietic Stem Cell Transplantation Cytopenias: Efficacy, Response Durability, and Cost Benefit of Early Drug Tapering | |
| Smolej | How I treat elderly or comorbid patients with chronic lymphocytic leukemia | |
| Zanwar et al. | Current therapeutic options in Waldenström macroglobulinemia | |
| WO2025122961A1 (en) | Methods for treating neutropenia | |
| Zielezińska et al. | Real-world data on switching from eltrombopag to romiplostim in Polish children with persistent and chronic immune thrombocytopenic purpura (ITP) | |
| Kahn et al. | A retrospective analysis of long-term survival in severe aplastic anemia patients treated with allogeneic bone marrow transplantation or immunosuppressive therapy with antithymocyte globulin and cyclosporin A at a single institution | |
| Scheinberg et al. | CLINICAL RESEARCH PROJECT | |
| Musch et al. | Randomized, double-blind, placebo-controlled, phase III study of | |
| WO1995016458A1 (en) | Il-6 therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20231208 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250508 Comment text: Request for Examination of Application |